CXF Stock Overview
A biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Chimerix, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.75 |
52 Week High | US$1.20 |
52 Week Low | US$0.75 |
Beta | 1.19 |
11 Month Change | -11.15% |
3 Month Change | -19.20% |
1 Year Change | -27.49% |
33 Year Change | -88.27% |
5 Year Change | -76.74% |
Change since IPO | -94.66% |
Recent News & Updates
Recent updates
Shareholder Returns
CXF | DE Biotechs | DE Market | |
---|---|---|---|
7D | -8.7% | 1.2% | 0.8% |
1Y | -27.5% | -16.0% | 6.1% |
Return vs Industry: CXF underperformed the German Biotechs industry which returned -16% over the past year.
Return vs Market: CXF underperformed the German Market which returned 6.1% over the past year.
Price Volatility
CXF volatility | |
---|---|
CXF Average Weekly Movement | 5.4% |
Biotechs Industry Average Movement | 6.5% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 10.5% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: CXF's share price has been volatile over the past 3 months.
Volatility Over Time: CXF's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 72 | Mike Andriole | www.chimerix.com |
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Chimerix, Inc. Fundamentals Summary
CXF fundamental statistics | |
---|---|
Market cap | €71.89m |
Earnings (TTM) | -€76.19m |
Revenue (TTM) | €37.82k |
1,825x
P/S Ratio-0.9x
P/E RatioIs CXF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CXF income statement (TTM) | |
---|---|
Revenue | US$41.00k |
Cost of Revenue | US$70.31m |
Gross Profit | -US$70.27m |
Other Expenses | US$12.32m |
Earnings | -US$82.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.92 |
Gross Margin | -171,387.80% |
Net Profit Margin | -201,443.90% |
Debt/Equity Ratio | 0% |
How did CXF perform over the long term?
See historical performance and comparison